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mineralization disorders affecting the
skin and arterial vasculature, there are
now as many as half a dozen genes that
can result in presentations often with
overlapping clinical features (Li and
Uitto, 2013). Nevertheless, NGS clearly
provides novel tools and strategies to
identify previously unrecognized candi-
date genes in patients with similar
phenotypic presentations, and refine-
ment of the bioinformatics analyses in
the context of clinical phenotypes may
allow identification of modifier genes
that contribute to the clinical hetero-
geneity of these diseases, including PXE.
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The Double Life of Connexin
Channels: Single Is a Treat
Roberto Bruzzone1,2
Although several genetic diseases are caused by mutations in channels
made by connexin family members, there has been little progress in the
development and validation of therapeutic options. An in vitro study in this issue
of JID suggests that an anti-malarial drug may be beneficial in keratitis-ichthyosis
deafness, a severe conexin channel disease associated with potentially fatal
recurrent infections.
Journal of Investigative Dermatology (2015) 135, 940–943; doi:10.1038/jid.2014.524
Ever since the report of a human genetic
disease linked to connexin mutations
more than 20 years ago, pharmacologi-
cal modulation of this class of channels
has acquired clinical relevance. Con-
nexins are special channels, as they
consist of oligomeric structures, termed
connexons or hemichannels, which can
either dock with cognate hemichannels
to form complete intercellular (gap junc-
tion) channels that provide ionic and
metabolic coupling between adjacent
cells, or function as unpaired connex-
ons, whose physiological role, if any,
remains to be firmly established (Saez
et al., 2003). Of note, dysregulated
hemichannel activity by mutated
connexins has been suspected to have
a pathogenic role in some diseases,
perhaps as a consequence of the
resulting loss of cell integrity (Xu and
Nicholson, 2013; Kelly et al., 2014). In
the current issue of JID by Levit et al.
(2015, this issue) describe the effect of a
molecule approved for anti-malarial
treatment, on some of the most
common Cx26 mutations that cause
keratitis-ichthyosis deafness (KID), a
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severe dominant disease associated with
recurrent infections that can evolve into
fatal septicemia. This report is an
important step toward validating the
pharmacological manipulation of
connexins to treat human disease.
How do connexins function?
Connexins are a family of integral mem-
brane proteins with four transmembrane
domains separated by two extracellular
loops, with N- and C-terminal regions
both facing the cytoplasm. Connexin are
the molecular correlate of gap junctions,
an oxymoron coined by Revel and
Karnovsky in 1967, who used
impregnation of tissue blocks with
lanthanum salts to visualize cell
junctions in which there was ‘‘a
minute gap between the external
leaflets’’ (Revel and Karnowsky, 1967).
At that time speculation was still
commonplace in scientific papers, and
they correctly surmised that the
junctions were the structural correlate
of ‘‘electrical interconnection’’ between
cells, which had been previously
described by Furshpan and Potter
(1959). The precise function of these
channels in any given tissue has been
inferred mainly from studies of
genetically modified mice and from the
phenotype of connexin-based human
diseases. It is now firmly established
that a good complement of connexins
is required during embryonic develop-
ment and throughout adult life for the
maintenance of lens transparency and
good vision. It is also clear that auditory
function and normal skin are also
dependent on connexins, but how
mutations in different connexins or even
in the same gene contribute to the
strikingly different phenotypes (compare
e.g., the consequences of dominant Cx26
mutations that can cause different skin
disorders with or without hearing
impairment) remains puzzling (Xu and
Nicholson, 2013). In addition, at least
nine connexin genes have been linked to
human genetic diseases of ear, skin, lens,
myelin, and other complex syndromes
(Kelly et al., 2014). In the case of
recessively transmitted connexin
diseases, the pathogenesis seems to be
linked primarily to simple loss of
function, exemplified by non-syndromic
deafness (Xu and Nicholson, 2013).
There is not much cellular flexibility to
increase channel activity and compen-
sate functionally for mutations that lead
to premature protein termination, altered
protein transport, or channels that are in a
locked configuration. On the other hand,
dealing with aberrant hemichannel
function may be more tractable.
Hemichannels: physiology and/or
pathology?
Much progress has been made in under-
standing the mechanisms that control
gating (viz., opening and closing) of
hemichannels. In a nutshell, the accep-
ted two-gate model posits that hemi-
channels are subject to different regula-
tion by a fast gate, which closes them to
a long-lasting substate, and a slow gate,
which is responsible for slow transitions
to fully closed channels. The latter has
been dubbed the ‘‘loop gate’’ because
of the possible involvement sequences
in the N-terminus, including transmem-
brane and extracellular loops, in closing
hemichannels (Harris and Contreras,
2014). Despite excellent biophysical
data, the development of molecules
that can distinguish between the two
gates of hemichannels has proven diffi-
cult. Thus, cell-based high-content/high-
throughput assays have been developed
for many different types of ion channels
using fluorescence readouts that
monitor membrane potential or Ca2þ
fluxes, but the results for connexin
aficionados have been modest, to say
the least.
Although hemichannel activity and
its regulation by intracellular and extra-
cellular messengers have been docu-
mented for some wild-type connexins
in vitro (Saez et al., 2003), there is no
genetic proof that this function is
required in vivo––i.e., that loss of
hemichannel but not gap junctional
function would result in a measurable
phenotype. In contrast, several groups,
including the White lab, have observed
enhanced hemichannel activity associ-
ated with dominant connexin mutations
(Kelly et al., 2014). In simple terms,
unopposed connexons are spending an
alarmingly high percentage of time in
the open state, and this is invariably
linked to a doomed fate awaiting cells
expressing those mutations in culture,
because it has long been postulated that
opening of connexin hemichannels
would lead to cell death (leakage
of metabolites, uncontrolled influx of
Ca2þ and so on). This phenotype
seems more amenable to pharmaco-
logical intervention, as the authors of
this report suggest by showing that
mefloquine, an approved anti-malarial
drug, can inhibit hemichannel opening.
Connexin diseases: What can be done?
How can this observation be pursued to
provide effective treatment for KID
patients? First, one needs to consider
the structure of the channel, where
mutations lie, and how they may affect
its structure. Levit et al. (2015) discuss
their findings in the framework of the
3.5A˚ resolution structure of the Cx26
gap junction channel (Maeda et al.,
2009), and their explanations hold.
Five of the seven mutations tested
(viz., all those causing KID with hemi-
channel activity) display sensitivity to
mefloquine blockade, albeit to different
extents. The two refractory mutations
are located in the hypothetical binding
site of mefloquine (Verselis and Srinivas,
2013) or in an atypical position
outside the consensus location of the
loop gate. These observations add
to the complexity of the problem, but
they may provide a blueprint for the
development of specific molecules.
Of note, all mutations were sensitive
to extracellular divalent cations, which
have been known for a long time to
significantly modulate loop gating
(Harris and Contreras, 2014), although
others have recently reported
altered inhibition of A40V hemi-
channels by Zn2þ and pH (Sanchez
et al., 2014).
What leaks out of an open hemichan-
nel, and what goes in? Those are the
questions. The mantra in the field for
years has been that molecules with a
molecular mass lower than 1,000 Da
would diffuse through gap junction
channels and, hence, hemichannels.
However, it is now appreciated that
connexins are endowed with special
behavioral codes, such as permselecti-
vity (e.g., Cx43 passes ATP much better
compared with Cx32, whereas the
Ca2þ -releasing messenger IP3 diffuses
more freely through Cx32 compared
with either Cx26 or Cx43), and gating
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(i.e., the regulation of channel opening
and its modulation by membrane poten-
tial and posttranslational modifications),
which has shown that distinct connexins
are substrates of different cellular
kinases and that phosphorylation can
be associated with either increase or
decreased permeability (Saez et al,
2003; Harris and Contreras, 2014).
Therefore, it is possible that these muta-
tions may not only alter the slow loop
gate, allowing hemichannels longer
dwelling times in the open configura-
tion, but also affect the types of
molecules that can permeate the open
channel, as well as the sensitivity to
regulatory signals. Are cells with unruly
Cx26 hemichannels releasing Danger-
Associated Molecular Patterns that
function as ‘‘find-me’’ signals to recruit
macrophages and trigger apoptosis, as
suggested for pannexin channels
(Chekeni et al., 2010), which share
some similarities to connexin hemi-
channels (Barbe et al., 2006), or simply
having massive Ca2þ influx that will
lead to cytotoxicity? These are not
byzantine questions, because they may
guide the development of more targeted
treatments that are tailored to the
specific pathophysiology of the disease.
Connexin blockers: hemichannels versus
gap junction channels
The reported correction of the aberrant
channel phenotype in primary keratino-
cytes isolated from a murine model of
KID (Levit et al., 2015) is encouraging
because it has been obtained with a
previously approved drug. Levit et al.
(2015) acknowledge that the overlap
between the hemichannel and gap
junction blocking activity remains the
most challenging aspect in the further
development of this class of molecules
for clinical use. Indeed, mefloquine burst
onto the connexin stage because it
blocked Cx36 intercellular channels
(Verselis and Srinivas, 2013), and we
should not forget that quinine derivatives
have also been shown to have parado-
xically enhancing effects on hemi-
channels made of other connexins
(Malchow et al., 1994), which shows
that their mode of action is not yet fully
understood. To be sure, the reported
selectivity of mefloquine over other
connexins expressed in the skin limits
the possibility of ‘‘off target’’ effects. The
inability to differentiate between hemi
and gap junction channels, however,
does not seem to pose an insurmoun-
table problem in this case. Thus, Cx26
gap junction channels appear to be
dispensable in human skin, as can be
inferred from the lack of a phenotype in
non-syndromic genetic deafness because
of the functionally incompetent Cx26
mutations (Xu and Nicholson, 2013),
and loss of Cx43 coupling in the skin,
owing to mutations or trans-dominant
effects, is only associated with a mild
cutaneous phenotype (Kelly et al., 2014).
Thus, the side effect of mefloquine
on Cx43 and Cx26 gap junction
channels in the skin should not prevent
further study of this compound as
treatment for KID.
The long road from bench to bedside
With all its limitations, mefloquine is a
good starting point, especially because
the White lab has already generated an
animal model of KID for in vivo studies.
Working with lipophilic drugs will not
be easy, but at least some obvious
experiments should be tried. For exam-
ple, would topical application of meflo-
quine be possible? Could it be given to
pregnant mice to delay/prevent the
appearance of lesions? It is likely that
these and other protocols are already
being employed. Future research should
remain firmly focused on existing
drugs that have documented evidence
of tolerability and an absence of side
effects in humans, because there will
never be a sufficient number of patients
with KID for a randomized clinical
trial. This, of course, may limit the
usefulness of any attempt to improve
mefloquine selectivity and potency, as
even the addition of a single oxygen
atom would transform the molecule into
a new drug with the need to undergo all
mandatory safety tests.
An additional molecule to be consid-
ered is tonabersat, a novel benzopyran
compound that was recently tested in
clinical trials for migraine with aura
(Sarrouilhe et al., 2014). Although
results were quite disappointing, the
drug was very well tolerated with very
few side effects. It remains to be seen
whether tonabersat may be an effec-
tive Cx26 hemichannel blocker and
whether there is sufficient selectivity
over other complements of skin
connexins. It would also be interesting
to know whether it may affect the
mutations that are refractory to meflo-
quine, and whether a combination
treatment may prove effective at lower
drug concentrations. The clinical goal
for patients with KID based on the lethal
G45E or A88V mutations is to provide a
treatment that will allow them to survive
early childhood (all of reported cases
with either of these mutations die,
most within the first few months after
birth) more than fully curing the disease.
It is to be hoped that this report
will generate renewed interest in the
therapeutic potential of drugs that
target connexins.
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When the Circadian Clock Meets the
Melanin Pigmentary System
Andrzej T. Slominski1,2, Ru¨diger Hardeland3 and Russel J. Reiter4
Silencing of BMAL1 and PER1 stimulates melanogenic activity of follicular and
epidermal melanocytes, indicating a novel role for peripheral circadian clock
processes in the regulation of melanin pigmentation. Linking the expression levels
of BMAL1/PER1 with changes in melanogenesis opens exciting opportunities to
study the role of the local molecular clock in modulation of melanocyte functions
in the hair follicle and the epidermis with attendant effects on epidermal barrier
functions in general.
Journal of Investigative Dermatology (2015) 135, 943–945; doi:10.1038/jid.2014.553
Silencing of the BMAL1 and PER1
stimulates melanogenic apparatus in
the skin
In this issue, Hardman et al. (2015)
provide evidence for the involvement
of a peripheral circadian oscillator in
the control of human pigmentation.
The experiments were conducted
using micro-dissected hair follicles and
cultured primary skin melanocytes.
Although melanogenesis in the hair
follicle is anagen-associated (Slominski
and Paus, 1993), the role of the peri-
pheral clock was notably demonstrated
under the conditions independent of the
hair cycle (Hardman et al., 2015).
Conclusions were convincingly drawn
from silencing of either BMAL1 (brain
and muscle aryl hydrocarbon receptor
nuclear translocator-like 1) or PER1
(period 1), using respective small
interfering RNAs. These two proteins
are components of the circadian core
oscillator, in which a heterodimer
formed from BMAL1 and its interaction
partner CLOCK (circadian locomotor
output cycles kaput) stimulates the
expression of PER (period) and CRY
(cryptochrome) variants. These factors
jointly block BMAL1/CLOCK actions, a
fundamental basis for the cyclicity of
circadian oscillators. The BMAL1/
CLOCK heterodimer activates PER and
CRY expression by binding to an E-box
within the respective promoters. In
addition, BMAL1/CLOCK stimulates the
expression of various circadian-driven
genes carrying an E-box. Concerning
melanogenesis, E-boxes are found in
the genes of tyrosinase, tyrosinase-
related proteins 1 and 2, in which they
also act as binding sites of the
melanogenic master regulator MITF
(microphthalmia-associated transcrip-
tion factor; Slominski et al., 2004).
With regard to the circadian oscillator
mechanism, silencing of BMAL1 can be
expected to substantially decrease
PER1 expression. In a cycling oscillator,
PER/CRY heterodimers are the key
players of the negative feedback limb
downregulating BMAL1/CLOCK activity.
However, silencing of PER1 may not
necessarily lead to BMAL1 overexpres-
sion, as in knockdown experiments
the oscillator is more or less fixed in a
non-cycling phase of the artificially
deregulated oscillator.
Under these conditions, silencing of
either BMAL1 or PER1 led to remarkably
clear effects: increased pigmentation,
expression of tyrosinase, tyrosinase-
related proteins 1 and 2, and phosphor-
ylation of the melanogenic master
regulator MITF. Silencing of PER1
caused mostly stronger effects than that
of BMAL1, findings that may indicate a
greater importance of the PER protein in
stimulating melanogenesis, perhaps also
under cycling conditions. In addition to
the molecular data, increased numbers
of melanosomes, higher melanocyte
dendricity, and stimulation of melano-
some transfer to keratinocytes were
shown to result from PER1 silencing,
which likely indicates involvement of
extramelanocytic cutaneous signaling
systems (Slominski et al., 2012). Com-
parison of hair follicle explants with
melanocyte cultures allowed a dissec-
tion between cell-autonomous actions
and other effects requiring cell–cell inter-
actions. In the isolated melanocytes,
silencing of the core oscillator compo-
nents increased melanogenesis, whereas
gp100 expression and melanocyte den-
dricity were not substantially changed
and may thus require melanocyte–
keratinocyte interactions, as reviewed by
Slominski et al. (2004).
BMAL1 and PER1 affect
melanin pigmentation.
Central and peripheral regulators of
circadian rhythm
During recent years, abundant evidence
has accumulated regarding the impor-
tance of peripheral circadian oscillators
(Fu and Kettner, 2013; Hardeland,
2013; Reiter et al., 2014). Some of
these cellular clocks are to a variable
extent autonomous and do not receive a
direct input from the hypothalamic
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